Diligence memo · auto-generated · as of July 2, 2026
Inomagen Therapeutics, Inc.
Inomagen Therapeutics, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Inomagen Therapeutics, Inc. operates in Biotechnology, based in CHICAGO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Inomagen Therapeutics, Inc. has raised $540K in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $200K on 2014-11-12.
Most recent recorded round closed around 2025-06-05.
Valuation (modeled)modeled
Provath models Inomagen Therapeutics, Inc. at approximately $363K (range $75K–$923K). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.38× the median modeled value of Pre-Seed Biotechnology companies in 2025–2027 (79 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 63 months.
Last raise 13 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 12% of Biotechnology peers (4293 compared).
Modeled value ranks above 1% of those peers.
Closest niche peers: Illexcor Holdings, LLC, Reprogram Biosciences, Inc., Maxymune Therapeutics, Inc., EnZeta Immunotherapies, Inc., Eliaz Therapeutics Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.